Clarapath, a robotics company aimed at catalysing change in the way pathology laboratories process human and animal tissue, has announced the acquisition of Crosscope. Crosscope is a digital pathology company with a turnkey imaging solution providing best-in-class workflow tools and slide management along with artificial intelligence (AI) and machine learning (ML) technology to assist pathologists with better and faster decision-making.
The enhanced and integrated technologies add a new dimension for laboratory leaders and clinicians. The acquisition combines Clarapath's SectionStar, the first, fully automated, all-in-one tissue sectioning and transfer system with Crosscope's workflow and computational pathology tools enabling labs to deliver care faster, more cost effectively, and at higher quality.
"Clarapath is thrilled to welcome Crosscope to the Clarapath team. We believe that the combination of SectionStar's exceptional automated robotics with Crosscope's advanced workflow and computational pathology tools provide an end-to-end platform for more patient-centric care in human and animal health," said Eric Feinstein, CEO of Clarapath. "Our combined offering will solve some of the most pressing issues in the lab such as labor shortages, quality control challenges, and the rapidly increasing volume of samples needing review. We are equally excited about the global expansion of our engineering team in Bombay, India."
The Crosscope Dx software platform has been designed by pathologists, and aims to streamline the pathology process by enabling interoperability, storage, image management, and collaboration. The software provides end-to-end digital pathology, and advanced, integrated, and highly flexible workflow features with an open and scalable architecture.
Click here to read the original news story.